The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Commentary|Videos|March 15, 2026
How ctDNA Testing is Changing Lymphoma Treatment
Author(s)Hua-Jay "Jeff" Cherng, MD
Fact checked by: Paige Britt
MRD testing promises sharper DLBCL response tracking than PET scans, cutting false positives, biopsies, and guiding therapy as trials catch up.
Advertisement
In an interview with Targeted Oncology, Hua-Jay “Jeff” Cherng, MD, assistant professor of medicine in the lymphoma program in the Division of Hematology and Oncology at the Columbia University Irving Medical Center, discussed how circulating tumor DNA testing is changing the way doctors monitor response to treatment compared with traditional PET scans.
Advertisement
Related to this article
Anbal-cel demonstrated a 67.1% complete response rate in relapsed or refractory LBCL in the phase 1/2 CRC01-01 trial, evaluating dual PD-1 and TIGIT knockdown CAR T-cell therapy.
Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
New ACS Guidelines Push for Earlier Prostate Cancer Screening
3
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
4
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
5